Trials / Terminated
TerminatedNCT06320080
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
Phase Ib Clinical Study Evaluating the Efficacy and Safety of TQB2223 Injection Combined With Penpulimab Injection in the Treatment of Advanced Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. This is a phase Ib study aimed at evaluating the safety, tolerability, and immunogenicity characteristics of TQB2223 injection combined with AK105 injection in the treatment of advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2223 injection | TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody. |
| DRUG | Penpulimab Injection | Penpulimab Injection is an anti programmed death-1 (PD-1) antibody. |
Timeline
- Start date
- 2024-05-30
- Primary completion
- 2025-11-03
- Completion
- 2025-11-03
- First posted
- 2024-03-20
- Last updated
- 2025-11-21
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06320080. Inclusion in this directory is not an endorsement.